Program
ADV7103
A development code.
Its studies are mostly in Cystinuria · Acidosis, led by Advicenne Pharma.
Furthest: phase 3, since Aug 22, 20185 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Advicenne Pharma | 50 open or running | phase 3since Aug 22, 2018 | Aug 22, 2018 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 22, 2018First study: phase 3 study in Acidosis, Renal TubularFirst studyNCT03644706 · 3 enrolled · United States, Canada
- Jan 23, 2019Phase 3 study in Acidosis, Renal TubularNCT03831152 · United States
- Oct 18, 20192 phase 3 studies in CystinuriaNCT04137978, NCT04147871
- Feb 26, 2026Phase 1 study in EFFECT OF ADV7103 ON GASTRIC PHNCT07446881 · 12 enrolled · France
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07446881EFFECT OF ADV7103 ON GASTRIC PH · France | 1 | Completed | Mar 15, 2025 | 12 |
| NCT04147871Cystinuria · Belgium, France | 3 | Withdrawn | May 1, 2025 | 0 |
| NCT04137978Cystinuria · Belgium, France | 3 | Withdrawn | Jun 2025 | 0 |
| NCT03831152Acidosis, Renal Tubular · United States | 3 | Withdrawn | Jan 2025 | 0 |
| NCT03644706Acidosis, Renal Tubular · United States, Canada | 3 | Terminated | Dec 20, 2023 | 3 |
How it is read
Names in the registry
- “ADV7103”, 5 entries
Codes read as this program: ADV7103.
Conditions, from the studies’ own filings
- Cystinuria, 2 studies
- Acidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.